Identification of the Active Compound of Liu Wei Di Huang Wan for Treatment of Gestational Diabetes Mellitus via Network Pharmacology and Molecular Docking

Liu Wei Di Huang Wan (LWDHW) is a well-known Chinese herbal compound, which has been prescribed for the treatment of gestational diabetes mellitus (GDM). We sought to clarify the potential therapeutic effects of LWDHW against GDM. Differentially expressed genes (DEGs) in GDM were firstly identified...

Full description

Bibliographic Details
Published in:Journal of Diabetes Research
Main Authors: Yunqi Xiong, Qiutong Li, Xiuhui Chen, Ting Zhu, Qitian Lu, Guojing Jiang
Format: Article
Language:English
Published: Wiley 2022-01-01
Online Access:http://dx.doi.org/10.1155/2022/4808303
_version_ 1849635864759500800
author Yunqi Xiong
Qiutong Li
Xiuhui Chen
Ting Zhu
Qitian Lu
Guojing Jiang
author_facet Yunqi Xiong
Qiutong Li
Xiuhui Chen
Ting Zhu
Qitian Lu
Guojing Jiang
author_sort Yunqi Xiong
collection DOAJ
container_title Journal of Diabetes Research
description Liu Wei Di Huang Wan (LWDHW) is a well-known Chinese herbal compound, which has been prescribed for the treatment of gestational diabetes mellitus (GDM). We sought to clarify the potential therapeutic effects of LWDHW against GDM. Differentially expressed genes (DEGs) in GDM were firstly identified from the Gene Expression Omnibus (GEO) database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to reveal the biological functions of the DEGs. Subsequently, the LWDHW-compound–target network was constructed based on public databases to identify the relationship between the active components in LWDHW and the corresponding targets. Furthermore, gene functional analysis and protein–protein interaction (PPI) network construction were applied to investigate the function of potential targets and to evaluate hub genes. Finally, molecular docking was used to verify the binding activities between active ingredients and hub targets. Thirteen active components and 39 corresponding therapeutic target genes were obtained via network pharmacology analysis. The enrichment analysis demonstrated that the anti-GDM effect of LWDHW included oxidoreductase activity, involvement in renal system process, and regulation of blood pressure, which may be achieved through regulation of serotonergic synapses, vascular smooth muscle contraction, and neuroactive ligand–receptor interaction pathways. Additionally, molecular docking revealed that the main active component, Mu Dan Pi, exhibited the best affinity for proteins encoded by hub genes. This study applied network pharmacology analysis and molecular docking to display the multicomponent and multitarget characteristics of LWDHW in the treatment of GDM. Our findings provide novel insights into the pathogenesis of GDM and the therapeutic mechanisms of LWDHW against GDM.
format Article
id doaj-art-e8765e914d8f4dee8a4433f57a4f0b74
institution Directory of Open Access Journals
issn 2314-6753
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
spelling doaj-art-e8765e914d8f4dee8a4433f57a4f0b742025-08-20T02:21:38ZengWileyJournal of Diabetes Research2314-67532022-01-01202210.1155/2022/4808303Identification of the Active Compound of Liu Wei Di Huang Wan for Treatment of Gestational Diabetes Mellitus via Network Pharmacology and Molecular DockingYunqi Xiong0Qiutong Li1Xiuhui Chen2Ting Zhu3Qitian Lu4Guojing Jiang5Department of Obstetrics and GynaecologyDepartment of Obstetrics and GynaecologyDepartment of Obstetrics and GynaecologyDepartment of Obstetrics and GynaecologyDepartment of Obstetrics and GynaecologyDepartment of Obstetrics and GynaecologyLiu Wei Di Huang Wan (LWDHW) is a well-known Chinese herbal compound, which has been prescribed for the treatment of gestational diabetes mellitus (GDM). We sought to clarify the potential therapeutic effects of LWDHW against GDM. Differentially expressed genes (DEGs) in GDM were firstly identified from the Gene Expression Omnibus (GEO) database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to reveal the biological functions of the DEGs. Subsequently, the LWDHW-compound–target network was constructed based on public databases to identify the relationship between the active components in LWDHW and the corresponding targets. Furthermore, gene functional analysis and protein–protein interaction (PPI) network construction were applied to investigate the function of potential targets and to evaluate hub genes. Finally, molecular docking was used to verify the binding activities between active ingredients and hub targets. Thirteen active components and 39 corresponding therapeutic target genes were obtained via network pharmacology analysis. The enrichment analysis demonstrated that the anti-GDM effect of LWDHW included oxidoreductase activity, involvement in renal system process, and regulation of blood pressure, which may be achieved through regulation of serotonergic synapses, vascular smooth muscle contraction, and neuroactive ligand–receptor interaction pathways. Additionally, molecular docking revealed that the main active component, Mu Dan Pi, exhibited the best affinity for proteins encoded by hub genes. This study applied network pharmacology analysis and molecular docking to display the multicomponent and multitarget characteristics of LWDHW in the treatment of GDM. Our findings provide novel insights into the pathogenesis of GDM and the therapeutic mechanisms of LWDHW against GDM.http://dx.doi.org/10.1155/2022/4808303
spellingShingle Yunqi Xiong
Qiutong Li
Xiuhui Chen
Ting Zhu
Qitian Lu
Guojing Jiang
Identification of the Active Compound of Liu Wei Di Huang Wan for Treatment of Gestational Diabetes Mellitus via Network Pharmacology and Molecular Docking
title Identification of the Active Compound of Liu Wei Di Huang Wan for Treatment of Gestational Diabetes Mellitus via Network Pharmacology and Molecular Docking
title_full Identification of the Active Compound of Liu Wei Di Huang Wan for Treatment of Gestational Diabetes Mellitus via Network Pharmacology and Molecular Docking
title_fullStr Identification of the Active Compound of Liu Wei Di Huang Wan for Treatment of Gestational Diabetes Mellitus via Network Pharmacology and Molecular Docking
title_full_unstemmed Identification of the Active Compound of Liu Wei Di Huang Wan for Treatment of Gestational Diabetes Mellitus via Network Pharmacology and Molecular Docking
title_short Identification of the Active Compound of Liu Wei Di Huang Wan for Treatment of Gestational Diabetes Mellitus via Network Pharmacology and Molecular Docking
title_sort identification of the active compound of liu wei di huang wan for treatment of gestational diabetes mellitus via network pharmacology and molecular docking
url http://dx.doi.org/10.1155/2022/4808303
work_keys_str_mv AT yunqixiong identificationoftheactivecompoundofliuweidihuangwanfortreatmentofgestationaldiabetesmellitusvianetworkpharmacologyandmoleculardocking
AT qiutongli identificationoftheactivecompoundofliuweidihuangwanfortreatmentofgestationaldiabetesmellitusvianetworkpharmacologyandmoleculardocking
AT xiuhuichen identificationoftheactivecompoundofliuweidihuangwanfortreatmentofgestationaldiabetesmellitusvianetworkpharmacologyandmoleculardocking
AT tingzhu identificationoftheactivecompoundofliuweidihuangwanfortreatmentofgestationaldiabetesmellitusvianetworkpharmacologyandmoleculardocking
AT qitianlu identificationoftheactivecompoundofliuweidihuangwanfortreatmentofgestationaldiabetesmellitusvianetworkpharmacologyandmoleculardocking
AT guojingjiang identificationoftheactivecompoundofliuweidihuangwanfortreatmentofgestationaldiabetesmellitusvianetworkpharmacologyandmoleculardocking